CNS Dopamine Receptors: Effect of Prolyl-Leucyl-Glycinamide and Solubilization
Identifieur interne : 005026 ( Main/Exploration ); précédent : 005025; suivant : 005027CNS Dopamine Receptors: Effect of Prolyl-Leucyl-Glycinamide and Solubilization
Auteurs : Ram K. Mishra [Canada]Source :
- Nutrition and Health [ 0260-1060 ] ; 1984.
Abstract
In order to elucidate the mechanism of interaction of a peptide L-prolylleucyl-glycinamide (PLC) with dopamine receptors, we have studied the action of PLC on dopamine receptors in various brain regions. The results support the hypothesis that specific PLC binding sites exist in the central nervous system and these binding sites (receptors) have a modulatory effect on the sensitivity of dopamine receptors. It is also suggested that PLC and its active analogues warrant further vigorous and systematic clinical trials to establish their therapeutic efficacy in Parkinson's disease, neuroleptic drug induced tardive dyskinesia and related estrapyramidal motor disorders. Studies carried out on solubilized dopamine receptors and adenylate cyclase suggest that dopamine receptors sites coupled to neurolic drug action and adenylate cyclase linked receptor sites might be closely interrelated. The preliminary results on lymphocyte dopamine binding sites suggest an increase in binding in schizophrenic patients, however, receptor criteria (stereospecific binding, saturation, etc.) could not be met for these binding sites (see Rotstein et al., 1983, for details).
Url:
DOI: 10.1177/026010618400300306
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001C88
- to stream Istex, to step Curation: 001C88
- to stream Istex, to step Checkpoint: 002593
- to stream Main, to step Merge: 005A38
- to stream Main, to step Curation: 005026
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">CNS Dopamine Receptors: Effect of Prolyl-Leucyl-Glycinamide and Solubilization</title><author wicri:is="90%"><name sortKey="Mishra, Ram K" sort="Mishra, Ram K" uniqKey="Mishra R" first="Ram K." last="Mishra">Ram K. Mishra</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E65556C1F2B454E1EFD4D6CF112369916DE659AD</idno><date when="1984" year="1984">1984</date><idno type="doi">10.1177/026010618400300306</idno><idno type="url">https://api-v5.istex.fr/document/E65556C1F2B454E1EFD4D6CF112369916DE659AD/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001C88</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001C88</idno><idno type="wicri:Area/Istex/Curation">001C88</idno><idno type="wicri:Area/Istex/Checkpoint">002593</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">002593</idno><idno type="wicri:doubleKey">0260-1060:1984:Mishra R:cns:dopamine:receptors</idno><idno type="wicri:Area/Main/Merge">005A38</idno><idno type="wicri:Area/Main/Curation">005026</idno><idno type="wicri:Area/Main/Exploration">005026</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">CNS Dopamine Receptors: Effect of Prolyl-Leucyl-Glycinamide and Solubilization</title><author wicri:is="90%"><name sortKey="Mishra, Ram K" sort="Mishra, Ram K" uniqKey="Mishra R" first="Ram K." last="Mishra">Ram K. Mishra</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Departments of Psychiatry and Neurosciences, Faculty of Health Sciences, McMaster University, Hamilton, Ontario</wicri:regionArea><orgName type="university">Université McMaster</orgName><placeName><settlement type="city">Hamilton (Ontario)</settlement><region type="state">Ontario</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Nutrition and Health</title><idno type="ISSN">0260-1060</idno><idno type="eISSN">2047-945X</idno><imprint><publisher>SAGE Publications</publisher><pubPlace>Sage UK: London, England</pubPlace><date type="published" when="1984">1984</date><biblScope unit="volume">3</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="175">175</biblScope><biblScope unit="page" to="187">187</biblScope></imprint><idno type="ISSN">0260-1060</idno></series><idno type="istex">E65556C1F2B454E1EFD4D6CF112369916DE659AD</idno><idno type="DOI">10.1177/026010618400300306</idno><idno type="ArticleID">10.1177_026010618400300306</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0260-1060</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In order to elucidate the mechanism of interaction of a peptide L-prolylleucyl-glycinamide (PLC) with dopamine receptors, we have studied the action of PLC on dopamine receptors in various brain regions. The results support the hypothesis that specific PLC binding sites exist in the central nervous system and these binding sites (receptors) have a modulatory effect on the sensitivity of dopamine receptors. It is also suggested that PLC and its active analogues warrant further vigorous and systematic clinical trials to establish their therapeutic efficacy in Parkinson's disease, neuroleptic drug induced tardive dyskinesia and related estrapyramidal motor disorders. Studies carried out on solubilized dopamine receptors and adenylate cyclase suggest that dopamine receptors sites coupled to neurolic drug action and adenylate cyclase linked receptor sites might be closely interrelated. The preliminary results on lymphocyte dopamine binding sites suggest an increase in binding in schizophrenic patients, however, receptor criteria (stereospecific binding, saturation, etc.) could not be met for these binding sites (see Rotstein et al., 1983, for details).</div></front></TEI><affiliations><list><country><li>Canada</li></country><region><li>Ontario</li></region><settlement><li>Hamilton (Ontario)</li></settlement><orgName><li>Université McMaster</li></orgName></list><tree><country name="Canada"><region name="Ontario"><name sortKey="Mishra, Ram K" sort="Mishra, Ram K" uniqKey="Mishra R" first="Ram K." last="Mishra">Ram K. Mishra</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005026 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005026 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:E65556C1F2B454E1EFD4D6CF112369916DE659AD
|texte= CNS Dopamine Receptors: Effect of Prolyl-Leucyl-Glycinamide and Solubilization
}}
| This area was generated with Dilib version V0.6.29. |  |